CenterBook Partners’s Humacyte HUMA Stock Holding History

CenterBook Partners’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$64.8K	Buy	+82,979	New	+$76.9K	﹤0.01%	693
2025 Q4	–	Sell	-283,627	Closed	-$494K	–	613
2025 Q3	$494K	Sell	283,627 -3,146,628	-92%	-$6.16M	0.02%	482
2025 Q2	$7.17M	Buy	3,430,255 +2,007,743	+141%	+$3.86M	0.4%	56
2025 Q1	$2.43M	Buy	1,422,512 +142,673	+11%	+$536K	0.15%	170
2024 Q4	$6.46M	Buy	+1,279,839	New	+$6.33M	0.39%	77
2022 Q3	–	Sell	-41,470	Closed	-$133K	–	416
2022 Q2	$133K	Sell	41,470 -4,282	-9%	-$23.8K	0.03%	370
2022 Q1	$323K	Buy	45,752 +22,046	+93%	+$128K	0.12%	277
2021 Q4	$172K	Buy	+23,706	New	+$234K	0.1%	272

Other funds holding HUMA

Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

CenterBook Partners's HUMA Position: Q2 2026 in Review

CenterBook Partners opened a new position in Humacyte (HUMA) in Q2 2026: 82,979 shares worth $64.8K. The stake represents ﹤0.01% of the portfolio and ranks #693 among its holdings. This is a return to the name: CenterBook Partners previously reported a position in HUMA as recently as Q3 2025.

CenterBook Partners first reported a position in HUMA in Q4 2021 and has held it in 8 quarters since. The position peaked at $7.17M in Q2 2025. 162 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

CenterBook Partners held 82,979 shares of Humacyte worth $64.8K as of Q2 2026.
Humacyte was a new CenterBook Partners position in Q2 2026.
Humacyte made up ﹤0.01% of CenterBook Partners's portfolio in Q2 2026, its #693 holding.
CenterBook Partners first reported a position in Humacyte in Q4 2021 and has held it in 8 quarters since.
CenterBook Partners's Humacyte position peaked at $7.17M in Q2 2025.
162 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.